- Home
- HNRG vs MLYS Comparison
HNRG vs MLYS Comparison
Compare HNRG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- MLYS
- Stock Information
- Founded
- HNRG 1949
- MLYS 2019
- Country
- HNRG United States
- MLYS United States
- Employees
- HNRG N/A
- MLYS N/A
- Industry
- HNRG Coal Mining
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- MLYS Health Care
- Exchange
- HNRG Nasdaq
- MLYS Nasdaq
- Market Cap
- HNRG 551.9M
- MLYS 510.6M
- IPO Year
- HNRG N/A
- MLYS 2023
- Fundamental
- Price
- HNRG $10.99
- MLYS $9.56
- Analyst Decision
- HNRG Strong Buy
- MLYS Strong Buy
- Analyst Count
- HNRG 2
- MLYS 2
- Target Price
- HNRG $15.00
- MLYS $27.00
- AVG Volume (30 Days)
- HNRG 465.3K
- MLYS 292.0K
- Earning Date
- HNRG 03-12-2025
- MLYS 02-12-2025
- Dividend Yield
- HNRG N/A
- MLYS N/A
- EPS Growth
- HNRG N/A
- MLYS N/A
- EPS
- HNRG N/A
- MLYS N/A
- Revenue
- HNRG $429,359,000.00
- MLYS N/A
- Revenue This Year
- HNRG N/A
- MLYS N/A
- Revenue Next Year
- HNRG $7.22
- MLYS N/A
- P/E Ratio
- HNRG N/A
- MLYS N/A
- Revenue Growth
- HNRG N/A
- MLYS N/A
- 52 Week Low
- HNRG $4.33
- MLYS $8.58
- 52 Week High
- HNRG $14.00
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- HNRG 46.83
- MLYS 42.42
- Support Level
- HNRG $10.80
- MLYS $8.98
- Resistance Level
- HNRG $11.50
- MLYS $10.75
- Average True Range (ATR)
- HNRG 0.60
- MLYS 0.72
- MACD
- HNRG 0.08
- MLYS 0.02
- Stochastic Oscillator
- HNRG 38.57
- MLYS 27.49
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.